



Use of Cell-Penetrating Peptides in Dendritic Cell-Based Vaccination

Sangho Lim^{1,2#}, Ja-Hyun Koo^{1,2#} and Je-Min Choi^{1,2*}

¹Department of Life Science, College of Natural Sciences, Hanyang University, Seoul 04763, Korea, ²Research Institute for Natural Sciences, Hanyang University, Seoul 04763, Korea

Cell-penetrating peptides (CPPs) are short amino acids that have been widely used to deliver macromolecules such as proteins, peptides, DNA, or RNA, to control cellular behavior for therapeutic purposes. CPPs have been used to treat immunological diseases through the delivery of immune modulatory molecules *in vivo*. Their intracellular delivery efficiency is highly synergistic with the cellular characteristics of the dendritic cells (DCs), which actively uptake foreign antigens. DC-based vaccines are primarily generated by pulsing DCs *ex vivo* with various immunomodulatory antigens. CPP conjugation to antigens would increase DC uptake as well as antigen processing and presentation on both MHC class II and MHC class I molecules, leading to antigen specific CD4⁺ and CD8⁺ T cell responses. CPP-antigen based DC vaccination is considered a promising tool for cancer immunotherapy due to the enhanced CTL response. In this review, we discuss the various applications of CPPs in immune modulation and DC vaccination, and highlight the advantages and limitations of the current CPP-based DC vaccination.

[Immune Network 2016;16(1):33-43]

Keywords: Cell-penetrating peptide, Dendritic cell, Vaccination, Immune modulation

INTRODUCTION

The cellular plasma membrane restricts the internalization of macromolecules from the outside environment. As such, several methods have been developed to facilitate the delivery of macromolecules into cells such as the use of liposomes, electroporation, and viral transfection. Cell-penetrating peptides (CPPs), which are generally composed of 4~30 basic amino acid rich sequences, are promising tools for delivering macromolecules into the cells (1-3).

In 1965, it was demonstrated that basic amino acid-rich histones and basic poly-amino acids can stimulate the internalization of albumin into tumor cells (4). Later studies showed that conjugation of poly-L-lysine to albumin enhanced cellular uptake (5). In 1988, cell membrane penetration of trans-acting activator of transcription (TAT) protein from human immunodeficiency virus-1 (HIV-1) was observed (6). It was shown that the arginine and lysine rich domain of TAT was critical for membrane penetration (7), and covalent binding of this domain with other proteins induced cellular uptake of proteins (8). These studies led to the identification of a number of CPPs including VP22, a CPP derived from viral protein (9,10); penetratin derived from the antennapedia, a drosophila homeoprotein (11,12); and transportan, derived from a neuropeptide (13). In addition to these natural sequences, synthetic CPPs such

Received on December 13, 2015. Revised on January 21, 2016. Accepted on January 26, 2016.

© This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

*Corresponding Author. Je-Min Choi, Department of Life Science, College of Natural Sciences, Hanyang University, 222, Wangsimni-ro, Seongdong-gu, Seoul 04763, Korea. Tel: 82-2-2220-4765; Fax: 82-2-2299-3495; E-mail: jeminchoi@hanyang.ac.kr

#These authors contributed equally to this work.

Abbreviations: CPP, Cell-penetrating peptide; DCs, Dendritic cells; TAT, trans-acting activator of transcription; MAP, model amphipathic peptide; NLS, nuclear localization sequence; ER, endoplasmic reticulum; GAGs, glycosaminoglycans

as poly-arginine (14), model amphipathic peptide (MAP) (15), and TP2 (16) were also generated. These CPPs are internalized across the plasma membrane alone or together with macromolecules such as proteins and nucleic acids.

The mechanism of internalization is still not fully understood. However, it is known that small CPPs can be internalized by both endocytosis and direct translocation across the membrane whereas large CPP-cargo molecules are internalized only via the endocytic pathway (2,17,18). After internalization, the CPP-cargo molecules enclosed in endosomes fuse with the lysosome. However, due to as yet unknown natural properties of some CPPs or modifications such as conjugation with chemicals escaping from the endosome or amino acid sequences, CPPs can escape from the endosome and diffuse into the cytoplasm before lysosome fusion (1,19). Because of the basic amino acid-rich characteristic of CPPs, similar to the nuclear localization sequence (NLS), some CPPs can translocate into the nucleus and as such, transcription factors and plasmid DNAs are often used as cargo for CPPs (20,21).

Various therapeutic approaches have been applied using CPPs (2,17,22). Delivery of biologically active proteins is the most common approach. Chemical conjugation or CPP sequence addition at the N- or C-terminal of the protein induces cell internalization. Addition of an 11 amino acid TAT sequence to the N-terminal of 116-kDa β -galactosidase (β -gal) led to *in vitro* and *in vivo* cellular internalization of the recombinant TAT- β -gal (8). Owing to their positively charged amino acid-rich characteristics, CPPs can bind to negatively-charged nucleic acids (23). Several studies have explored delivery of plasmid DNA (pDNA) using CPPs and a simple mixture of pDNA with TAT facilitated the transfection of pDNA into cells (24,25). CPPs can also be used to transfect siRNA into cells (26,27). However, the transfection efficiency of CPP/nucleic acid complexes is low, and various methods have been developed to overcome this limitation, such as the addition of chloroquine, which induces endosomal escape, (28) and using CPP-conjugated RNA binding domain (RBD) for RNA delivery (29,30). Also small molecules such as taxol and methotrexate conjugated with CPPs showed improved drug efficiency. Because of decreased transport and increased efflux. It was reported that various tumor cells showed resistant to chemotherapy while CPP-conjugated small molecules increased drug delivery into cells and showed better therapeutic efficiency to tumor cells (31,32).

From the cargo delivery properties, there are CPP-based drugs undergoing clinical trials. TAT-linked c-Jun N-terminal kinase (JNK)-inhibiting peptide, called XG-102, is undergoing clinical phase III that targeted different diseases such as inflammation and hearing loss. KAI-9803 and KAI-1678 are TAT-CPP conjugated protein kinase C inhibitor peptide for myocardial infarction and pain. Clinical phase II for these molecules were completed. TAT-CPP using botulinum toxin type A, named RT001, is currently in clinical phase III for treatment of wrinkles (17). Besides these molecules, various molecules using CPPs have been underwent or are currently in clinical phase but there are no FDA approved molecules yet.

One of the most promising therapeutic approaches using CPP is its application in dendritic cell (DC) vaccine based treatment of cancer and infectious diseases. The predominant method of DC immunization involves the use of antibodies or molecules that target surface receptors such as C-type lectin receptors, FC receptors, and integrin. After interaction with these receptors, conjugated antigens are internalized by endocytosis. The endosome with the antigen is fused with the lysosome and antigens are degraded by protease, and then loaded onto MHC class II. Moreover, some DCs can cross-present antigens on MHC class I to CD8⁺ T cells; however, the mechanism is not clearly understood. Endocytosed antigens can also escape into the cytoplasm, undergo proteasome degradation, and ultimately transported to the endoplasmic reticulum (ER) (33,34). Accordingly, CPP-antigens can be internalized into DCs and loaded onto MHC molecules. Because CPP-antigens can be internalized into DCs without receptor targeting molecules, this method is independent of receptor expression. Also, the natural propensity for endosome escape demonstrated by some CPPs enable antigen presentation by MHC class I molecules, leading to more efficient CTL responses than the naked antigen pulsing method. In this review, we highlight various CPP applications for immune modulation including DC-based vaccination, and discuss the advantages of using CPPs in dendritic cell biology.

CPP APPLICATIONS IN IMMUNE MODULATION

Several approaches to immune modulation using CPPs have been attempted. One of the initial strategies was delivery of dominant-negative signaling molecules that can competitively inhibit the function of endogenous proteins

in immune cells. Ras is an important signaling protein for Th2 differentiation after TCR stimulation (35). Intranasal delivery of dominant-negative Ras (dnRas) using TAT-CPP blocked OVA induced eosinophilia and lymphocyte accumulation in the bronchoalveolar lavage (BAL) fluid. Lung histology demonstrated a decrease in cellular infiltration and mucus-containing epithelial cells in TAT-dnRas pretreated mice (36). Phosphoinositide 3-kinase (PI3K) signaling is an important pathway downstream of the costimulatory molecules in T cells and B cells, which contributes to asthma by phosphorylation of PtdInsP2, immune cell recruitment, activation, and apoptosis. PI3K is composed of a catalytic subunit and adaptor protein. p85 α is a PI3K adaptor protein and p85 α knockout mice die within a few weeks of birth due to immunodeficiency (37). After intraperitoneal injection of dominant-negative p85 α which lacks the binding site for the catalytic subunit conjugated to TAT-CPP, lymphocyte and eosinophil numbers were reduced. In addition, the level of IL-4 and IL-5 decreased in the BAL fluid in OVA immunized mice (38). ZAP-70 is a proximal TcR signaling molecule that induces phosphorylation of downstream molecules such as LAT and SLP-76 (39). Mutation of tyrosine 318 (Y318F mutant), which is the amino acid for phosphorylation, impairs T cell activation signaling. Treatment of dominant negative ZAP-70-Y318F conjugated with human derived CPP, named Hph-1, reduced phosphorylation of TcR signaling and inhibited secretion of IL-2 after TcR stimulation (40). STAT-6, a cytokine receptor that regulates IL-4/IL-13 gene expression, is also critical to allergic airway diseases and T cells from STAT-6 knockout mice cannot be differentiated into Th2 cells (41). Intranasal administration of a TAT-CPP conjugated dominant-negative STAT-6 peptide induced the asthma model in mice through OVA stimulation. Moreover, there was a significant decrease in the number of immune cells from BAL fluid and mucus production in the lung (42). Retinoic acid-related orphan receptor gamma t (ROR γ t) is a lineage specific transcription factor for Th17 differentiation (43). Dominant negative truncated form of ROR γ t without its DNA binding conjugated with Hph-1-CPP showed reduced IL-17 production and Th17 differentiation results amelioration of experimental autoimmune encephalomyelitis (EAE) (44).

In addition to delivering dominant negative molecules into cells, intracellular delivery of negative regulators of key signaling pathways of the immune system was another

strategy utilized for CPP mediated immune modulation. Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) is expressed in activated T cells and regulatory T cells, and functions to down-regulate the immune system (45). Treatment with the cytoplasmic domain of CTLA-4 (ctCTLA-4) recombinant protein conjugated to Hph-1-CPP inhibited IL-2 secretion from activated T cells. Intranasal administration of Hph-1-ctCTLA-4 reduced Th2 cytokines as well as the number of immune cells from BAL fluid. Inhibition of inflammatory cell infiltration and mucus containing epithelial cells was also observed in an OVA induced mouse asthma model (46). Intravenous injection of Hph-1-ctCTLA-4 also inhibited inflammation and bone destruction in a collagen induced autoimmune arthritis model through inhibition of T cell responses (47). Another application involved intravenous injection of ctCTLA-4 conjugated with dNP2-CPP, which can penetrate the blood-brain barrier and deliver the protein into the brain and spinal cord in an experimental autoimmune encephalomyelitis (EAE) model. This resulted in reduced IFN- γ or IL-17A producing CD4⁺ T cells in the spinal cord, and ameliorated EAE (48). In other study, suppressor of cytokine signaling 3 (SOCS3) a repressor of IL-6 induced phosphorylation of STAT3 was linked with MTM-CPP and it showed inhibition of inhibited inflammatory liver injury induced by enterotoxin B (SEB), lipopolysaccharide (LPS), and lectin concanavalin A (ConA) (49).

Foxp3, a master transcription factor for regulatory (Treg) T cells, was generated as a recombinant protein conjugated to tandem repeated form of Hph-1-CPP, named HHph-1. It could be translocated into the nucleus and convert CD4⁺CD25⁻ T cells to Treg like CD25^{high}CTLA-4^{high} cells. In addition, systemic delivery of HHph-1-Foxp3 suppressed allergic airway inflammation and autoimmune responses in a colitis model and in scurfy mice (50).

Chimeric peptide based immune modulation by targeting transcription factors has also been attempted. NF- κ B is an important transcription factor that regulates multiple genes related to immune responses (51). In pharmaceutical studies, targeting NF- κ B is a popular strategy for regulating immune responses. NF- κ B essential modulator (NEMO) is a subunit of the I κ B kinase complex (IKK) that activates NF- κ B through phosphorylation (52). The NEMO binding domain (NBD) is an 11-amino acid peptide that can block the interaction of NEMO with IKK and inhibit NF- κ B activation. NBD conjugated to TAT-CPP inhibited

LPS-induced IKK activity, accelerated constitutive apoptosis of human polymorphonuclear neutrophils (PMNs), and inhibited LPS-delayed apoptosis (53). Nuclear factor of activated T cells (NFAT) is a key transcription factor for T cell activation and IL-2 production (54). The VIVIT peptide was identified as an inhibitor for NFAT signaling through the interfering interaction of calcineurin with NFAT (55). Intranasal delivery of a Sim-2-VIVIT peptide inhibited airway inflammation in an OVA-induced experimental asthma model (56). Mitogen-activated protein kinase activated protein kinase 2 (MK2) is a serine/threonine kinase that regulates cytokine expression at the transcriptional and post-translational levels by stabilizing the mRNA of inflammatory cytokines (57). The MK2 inhibitory peptide, KKKALNRQLGVAA, conjugated to various CPPs blocked the production of inflammatory cytokines such as IL-6 and TNF α in LPS stimulated macrophages (58).

Nucleotides have also been delivered into cells using CPPs for immune regulation. When siRNA targeting mitogen-activated protein kinase (MAPK) was conjugated to TAT-CPP or penetratin-CPP and delivered into the cells, MAPK mRNA levels were reduced by siRNA-CPP *in vitro*; however, intratracheal administration of siRNA-CPP did not affect MAPK mRNA levels *in vivo* (59). Decoy oligonucleotides that consist of a double-stranded short oligonucleotide corresponding to a gene promoter can block the binding of transcription factors to promoter regions. A NF- κ B decoy was hybridized to the peptide nucleic acid (PNA) and PNA was linked to transportan-CPP by disulfide bond. Following intracellular delivery, this complex blocked NF- κ B binding activity and decreased IL-1 β induced IL-6 mRNA (60).

Methotrexate (MTX) is a small molecule drug for treatment of rheumatoid arthritis. However, the long-term systemic administration of MTX may induce serious adverse effects. In this reason, previously MTX conjugated with cell-penetrating peptide, Hph-1, was used for transcutaneous topical administration for rheumatoid arthritis. This cell-penetrating MTX showed successful therapeutic effects in collagen induced arthritis model by inhibiting pro-inflammatory cytokine expressions and inflammation (61). Cyclosporine A (CysA) was also conjugated with poly-arginine (R7) to enhance its delivery efficiency *in vitro* and *in vivo*, especially topical skin delivery. It showed successful inhibition of T cell activation and ear inflammation (62).

As we summarized, various therapeutic cargo molecules including proteins, peptides and nucleotides have been applied in immune disease models targeting key functional molecules in immune cell activation and differentiation. There have also been various clinical trials under investigation for the commercialization of CPP conjugated bio-drugs in immune diseases (17). Biologic drug targeting of intracellular events using CPP could open a new area of investigation into drug development.

DC VACCINATION WITH CELL-PENETRATING PEPTIDES

Conventional DC vaccination method

Dendritic cells are the major mediators between innate and adaptive immune responses. They can initiate antigen specific adaptive immune responses in their role as antigen presenting cells (63). Because of this critical function, they are considered potent immunotherapeutic agents, especially for treating various cancers (64). In 1995, the first attempt at *ex vivo* DC-based cancer vaccination was reported for the treatment of melanoma (65), and since then, numerous clinical trials using DC vaccination have been completed or are currently underway.

ex vivo DC manipulation is the most common methodology used in clinical trials. This requires the isolation of DCs or their precursors from patients or donors (66). The sources of DCs are autologous or allogeneic cells. Autologous cells have the advantage of no risk of graft-versus-host disease but allogeneic cells could induce efficient immune boosting (67,68) because the isolated cells may have immune suppressive characteristics (69,70). After obtaining the cells, manipulation is performed, including appropriate antigen loading (71), maturation, and activation (72,73). Successfully manipulated DCs are then reinjected into patients by various routes including intradermal/subcutaneous (74), intranodal (75), intratumoral (76,77), or intravenous (78) injection. For example, to treat melanoma, mature DCs (79), CD34⁺ cells (80), or monocyte-derived DCs (81) pulsed with peptide antigen showed significant immune responses. In addition to using peptide antigen, killed allogeneic tumor cells were also used as antigens and they demonstrated successful immunogenicity, clinical responses and prolonged survival (82). DC vaccination approaches have been used to treat other types of cancer including prostate cancer (83), colon cancer (84), or glioma

(85), and multiple myeloma (86), and have demonstrated successful immunogenicity and T cell responses.

Another methodology for DC vaccination is the *in vivo* DC targeting approach. Because *ex vivo* DC manipulation and reinjection in patients is generally regarded as an expensive and laborious process (66), the injection of antigen coupled to DC cell surface targeting monoclonal antibodies (mAb) has been applied. The use of DEC205 (87), DC surface lectins DCIR (88), dectin 1 (89), CLEC9A (90), and Langerin (91) targeting antibodies coupled to antigens was evaluated. Animal studies demonstrated that antigen delivery using these molecule specific antibodies induced anti-tumor immunity involving T cell responses and antigen specific antibody responses. This approach was also used for anti-viral vaccination using an anti-DEC205 antibody coupled to the HIV gag protein (92). This approach was also successful, demonstrating induction of robust T cell immunity in nonhuman primates. However, this method can only be used with known antigen because the cells need to be prepared experimentally prior to injection. This is in contrast to *ex vivo* DC manipulation that utilizes tumor cell lysates or apoptotic cell bodies as antigen. Also, to induce efficient DC activation and robust adaptive immunity, adjuvant is needed (93). Furthermore, the impact of the interaction between cell surface molecules on DCs and targeting mAbs is carefully characterized to induce only accurate and expected immune responses (94).

DC vaccination using cell-penetrating peptides

Although *ex vivo* DC manipulation has demonstrated clinical success, its efficiency has not been regarded as effective. It has been reported that enhancing antigen delivery efficiency and long lasting antigen presentation could improve this weakness by using cell-penetrating peptide conjugated antigens. For example, CPP1 (AAVLLPVLLVLLAAP) conjugated peptide antigen pulsed DCs induced successful anti-tumor responses *in vivo* with much higher efficiency than only antigen pulsed DCs (95). This suggests that CPP mediated antigen delivery in the cytoplasm facilitates antigen presentation by newly synthesized MHC class I molecules, which lead to long-term immunological responses.

Accordingly, one of best-characterized CPPs, TAT, has been used as part of various DC vaccination strategies. TAT fused Leishmania homolog of receptors for activated C kinase (LACK) was used to induce immune responses

against leishmaniasis through DC vaccination (96). TAT-LACK pulsed DCs induced higher proliferation of CD8⁺ T cells and IFN-gamma releasing Th1 or Tc1 cells than LACK only pulsed DCs, suggesting that TAT enhanced vaccination efficiency. In another study, the OVA protein fused with TAT (TAT-OVA) induced antigen specific cytotoxic lymphocytes (CTL) while OVA lacking TAT could not enter the MHC class I presentation pathway (97). In a breast tumor model, mature TAT-Her/neu pulsed DCs induced Her2/neu specific CD8⁺ T cell responses and CD4⁺ T cell responses (98).

Another CPP, called penetratin (Antp), a 16-mer peptide, has also been used for DC vaccination, and its efficacy has been confirmed through *in vitro* and *in vivo* experiments (99). DCs pulsed with penetratin linked to the CD4 or CD8 specific OVA epitope for 24 h and co-cultured with OT-I or OT-II cells successfully induced T cell proliferation. In addition, *in vivo* injection of the penetratin-antigen complex induced an immune response against OVA expressing tumor cells, and its ability to reduce tumor size was enhanced through adjuvant co-injection. Poly-arginine (R9) has also been efficiently applied in DC vaccination strategies, in terms of inducing antigen specific T cell proliferation and reducing tumor size (100). Recently, a new CPP named, z12 was used for direct antigen delivery *in vivo* to dendritic cells, and showed robust CD4⁺ and CD8⁺ T cell mediated antitumor immune responses (101).

Collectively, these studies suggest that CPP can be used for DC vaccination against infectious diseases or various cancers. Although CPPs can only be coupled to known antigens for preparing fusion proteins or peptides, CPP-antigen delivery efficiency and location in the cytoplasm can significantly enhance the efficiency of cytotoxic T lymphocyte (CTL) activation, presumably via cross-presentation. This DC vaccination method has been shown to be more effective than naked antigen pulsing methods.

Mechanisms of CPP-antigen delivery and processing

CPP can interact with cell surface molecules such as glycosaminoglycans (GAGs), which are negatively charged-cell surface glycoproteins (102,103). Most well characterized CPPs are positively charged amino acid based sequences. Under physiological conditions, their electrostatic interaction with GAGs can easily be formed, and this CPP-cell surface molecule interaction induces internal-

ization of cargo molecules into the cytoplasm. The internalization mechanisms are defined as macropinocytosis or clathrin-, caveolin-mediated endocytosis, which lead to the formation of endosomes (17). In DC vaccination using CPPs, these mechanisms significantly enhance antigen delivery efficiency compared to free antigen delivery systems, and mimic the antigen presentation pathway of naturally phagocytosed antigens.

Because internalized CPP conjugated antigens in DCs are in the endosome, they can be encountered by two pathways: MHC class II presentation or MHC class I presentation by cross-presentation (104). When DCs uptake an antigen, the phagocytosed endosome fuses with the lysosome and the antigen is then degraded into peptides. In this late endosome, antigens can be loaded onto MHC class II and presented on the surface of DCs. CD4⁺ T cells can recognize this MHC class II-antigen complex for in-

ducing adaptive immune responses. Also, in terms of DC vaccination, MHC class I cross-presentation is an important process for recruiting CD8⁺ T cell responses against specific antigens. Antigens that escape from endosomes are degraded through proteasomal degradation and can be loaded on MHC class I in cytosolic vesicles through the transporter associated with antigen processing 2 (TAP2) molecule. Degraded antigen peptides can also be transported into the endoplasmic reticulum (ER) through the TAP 1 molecule, and loaded on MHC class I molecules in the ER (105). The MHC class I-antigen complex is presented on the DC surface for CD8⁺ T cell recognition. Alternatively, antigens can be directly degraded in the endosome by phagosomal degradation and loaded on MHC class I molecules (106).

Several previous studies demonstrated that endocytosed CPP-cargo proteins exhibit functions as enzymes, tran-




Figure 1. The mechanism of dendritic cell-based vaccination using cell-penetrating peptides. Dendritic cells can uptake CPP-antigen more efficiently than free-antigen. CPP-antigen can interact with the surface of dendritic cells through negatively charged glycosaminoglycans (GAGs), which can induce micropinocytosis or other endocytic pathways (1). Both CPP-antigen and free-antigen can also be localized into the cytoplasm via micropinocytosis by DCs (1). CPP antigens can escape endosomes because of their unique characteristics (2), while free-antigen has relatively low opportunity for endosomal escape (3). Antigens remaining in the endosomes are then subjected to lysosomal degradation (4) and presented on MHC class II molecules (5). Escaped antigens are degraded through the proteasome (6) and can be transported into vesicles containing MHC class I via TAP2 (7) or the endoplasmic reticulum (ER) through TAP1 (8). In the ER-Golgi pathway, degraded antigens are loaded on the MHC class I (9), and this MHC class I-antigen complex is presented on the surface of dendritic cells (10, 11).

scription factors, or inhibitors suggesting that CPP-proteins can escape the endosome. For this reason, the CPP-antigen can also be processed for antigen presentation via the same pathways used for naturally occurring antigens (107). The cytosolic delivered antigen can be presented on MHC class I, and they play a critical role in the efficacy of DC vaccinations. Some amount of endocytosed CPP-antigen also can be trapped in the endosome and undergone phagosomal degradation and MHC class II or MHC class I presentation. Because CPPs use the endocytic pathways of dendritic cells, CPP-antigens could efficiently share antigen presentation mechanisms (Fig. 1).

Advantages and limitations of CPP coupling to antigens in DC vaccination

Previous studies demonstrate that CPP-mediated DC vaccination approaches are promising, especially *ex vivo* DC manipulation, because of the highly enhanced antigen delivery efficiency. It has been shown that R9 linked antigens can induce immune responses with higher efficiency than TAT, suggesting that higher cargo delivery ability leads to higher immune responses (100). In a recent paper, the *in vivo* immune response boosting ability by CPP-using DC vaccination was much higher than antigen only (101). It is presumably due to CPP linked cargo molecules is preferentially delivered into phagocytic cells compared to other immune cell types (48).

The advantage of cell-penetrating peptides over DC surface molecule specific antibody methods has been reported. A previous study demonstrated that delivery and cross presentation efficiency was not significantly different between a DC-SIGN targeting antibody and the CPP coupling method (108). Using *in vivo* delivery of CPP-antigen molecules to bypass the expensive and laborious *ex vivo* DC manipulation method does not overcome the issues of antigen specificity because despite the many advantages of CPPs, they are still regarded as a nonspecific delivery tool (109). Immunogenicity of CPP itself is still concerned as a critical limitation especially if it is originated from non-self while Hph-1-ctCTLA-4 which is human chimeric protein did not induce specific antibody (46). In addition, appropriate CPP-antigen coupling via covalent or non-covalent conjugation and its purification processes is another technical hurdle for versatile application. Nevertheless, the advantages of using CPP for DC vaccination are important for effective therapy and include efficient cyto-

solic delivery through endosome escape, induction of both CD4⁺ and CD8⁺ T cell responses, DC surface molecule independency, and high efficiency.

CONCLUSION

CPPs are considered an attractive therapeutic application tool and numerous approaches utilizing CPPs were reported to successfully treat various diseases in animal models. CPP coupling to antigens in DC vaccination strategies have also recently been highlighted in cancer therapy. CPP-tumor antigens for *ex vivo* DC manipulation efficiently enable induction of antigen specific effector T cell responses, including CTL responses. The direct application of CPP-antigen for *in vivo* targeting has also been successful in generating antigen specific immune responses. However, the current limitation of CPP coupling to a limited number of antigens and still less *in vivo* efficiency requires further investigation. A way of overcoming this limitation would be to use highly efficient CPP for *in vivo* delivery or various other coupling methods involving simultaneous use of several antigens in order to broaden its application. Based on the understanding of current DC vaccination strategies, we expect to develop successful therapeutic and/or preventive DC vaccinations for treatment of cancer or infectious diseases.

ACKNOWLEDGEMENTS

This study is supported by the Korea Health technology R&D project through the Korea Health Industry Development Institute (KHIDI) funded by the Ministry of Health & Welfare, Republic of Korea (HI14C0234).

CONFLICTS OF INTEREST

The authors have no financial conflict of interest.

REFERENCES

1. Erazo-Oliveras, A., N. Muthukrishnan, R. Baker, T. Y. Wang, and J. P. Pellois. 2012. Improving the endosomal escape of cell-penetrating peptides and their cargos: strategies and challenges. *Pharmaceuticals (Basel)* 5: 1177-1209.
2. Ramsey, J. D., and N. H. Flynn. 2015. Cell-penetrating peptides transport therapeutics into cells. *Pharmacol. Ther.* 154: 78-86.
3. Bechara, C., and S. Sagan. 2013. Cell-penetrating peptides: 20

- years later, where do we stand? *FEBS Lett.* 587: 1693-1702.
- Ryser, H. J. and R. Hancock. 1965. Histones and basic poly-amino acids stimulate the uptake of albumin by tumor cells in culture. *Science* 150: 501-503.
 - Shen, W. C., and H. J. Ryser. 1978. Conjugation of poly-L-lysine to albumin and horseradish peroxidase: a novel method of enhancing the cellular uptake of proteins. *Proc. Natl. Acad. Sci. U. S. A.* 75: 1872-1876.
 - Frankel, A. D., and C. O. Pabo. 1988. Cellular uptake of the tat protein from human immunodeficiency virus. *Cell* 55: 1189-1193.
 - Vives, E., P. Brodin, and B. Lebleu. 1997. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. *J. Biol. Chem.* 272: 16010-16017.
 - Schwarze, S. R., A. Ho, A. Vocero-Akbani, and S. F. Dowdy. 1999. *In vivo* protein transduction: delivery of a biologically active protein into the mouse. *Science* 285: 1569-1572.
 - Elliott, G., and P. O'Hare. 1997. Intercellular trafficking and protein delivery by a herpesvirus structural protein. *Cell* 88: 223-233.
 - Dilber, M. S., A. Phelan, A. Aints, A. J. Mohamed, G. Elliott, C. I. Smith, and P. O'Hare. 1999. Intercellular delivery of thymidine kinase prodrug activating enzyme by the herpes simplex virus protein, VP22. *Gene Ther.* 6: 12-21.
 - Derossi, D., A. H. Joliot, G. Chassaing, and A. Prochiantz. 1994. The third helix of the Antennapedia homeodomain translocates through biological membranes. *J. Biol. Chem.* 269: 10444-10450.
 - Joliot, A., C. Pernelle, H. agostini-Bazin, and A. Prochiantz. 1991. Antennapedia homeobox peptide regulates neural morphogenesis. *Proc. Natl. Acad. Sci. U. S. A.* 88: 1864-1868.
 - Pooga, M., M. Hallbrink, M. Zorko, and U. Langel. 1998. Cell penetration by transportan. *FASEB J.* 12: 67-77.
 - Wender, P. A., D. J. Mitchell, K. Pattabiraman, E. T. Pelkey, L. Steinman, and J. B. Rothbard. 2000. The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters. *Proc. Natl. Acad. Sci. U. S. A.* 97: 13003-13008.
 - Oehlke, J., A. Scheller, B. Wiesner, E. Krause, M. Beyermann, E. Klauschenz, M. Melzig, and M. Bienert. 1998. Cellular uptake of an alpha-helical amphipathic model peptide with the potential to deliver polar compounds into the cell interior non-endo-cytically. *Biochim. Biophys. Acta* 1414: 127-139.
 - Marks, J. R., J. Placone, K. Hristova, and W. C. Wimley. 2011. Spontaneous membrane-translocating peptides by orthogonal high-throughput screening. *J. Am. Chem. Soc.* 133: 8995-9004.
 - Koren, E., and V. P. Torchilin. 2012. Cell-penetrating peptides: breaking through to the other side. *Trends Mol. Med.* 18: 385-393.
 - Fonseca, S. B., M. P. Pereira, and S. O. Kelley. 2009. Recent advances in the use of cell-penetrating peptides for medical and biological applications. *Adv. Drug Deliv. Rev.* 61: 953-964.
 - El-Sayed, A., S. Futaki, and H. Harashima. 2009. Delivery of macromolecules using arginine-rich cell-penetrating peptides: ways to overcome endosomal entrapment. *AAPS J.* 11: 13-22.
 - Lim, S., W. J. Kim, Y. H. Kim, and J. M. Choi. 2012. Identification of a novel cell-penetrating peptide from human phosphatidate phosphatase LPIN3. *Mol. Cells* 34: 577-582.
 - Zaro, J. L., J. E. Vekich, T. Tran, and W. C. Shen. 2009. Nuclear localization of cell-penetrating peptides is dependent on endocytosis rather than cytosolic delivery in CHO cells. *Mol. Pharm.* 6: 337-344.
 - Regberg, J., A. Srimanee, and U. Langel. 2012. Applications of cell-penetrating peptides for tumor targeting and future cancer therapies. *Pharmaceuticals (Basel)* 5: 991-1007.
 - Bolhassani, A. 2011. Potential efficacy of cell-penetrating peptides for nucleic acid and drug delivery in cancer. *Biochim. Biophys. Acta* 1816: 232-246.
 - Hashida, H., M. Miyamoto, Y. Cho, Y. Hida, K. Kato, T. Kurokawa, S. Okushiba, S. Kondo, H. aka-Akita, and H. Katoh. 2004. Fusion of HIV-1 Tat protein transduction domain to poly-lysine as a new DNA delivery tool. *Br. J. Cancer* 90: 1252-1258.
 - Saleh, A. F., H. Aojula, Y. Arthanari, S. Offerman, M. Alkotaji, and A. Pluen. 2010. Improved Tat-mediated plasmid DNA transfer by fusion to LK15 peptide. *J. Control Release* 143: 233-242.
 - Andaloussi, S. E., T. Lehto, I. Mager, K. Rosenthal-Aizman, I. I. Oprea, O. E. Simonson, H. Sork, K. Ezzat, D. M. Copolovici, K. Kurrikoff, J. R. Viola, E. M. Zaghoul, R. Sillard, H. J. Johansson, H. F. Said, P. Guterstam, J. Suhorutsenko, P. M. Moreno, N. Oskolkov, J. Halldin, U. Tedebark, A. Metspalu, B. Lebleu, J. Lehtio, C. I. Smith, and U. Langel. 2011. Design of a peptide-based vector, PepFect6, for efficient delivery of siRNA in cell culture and systemically *in vivo*. *Nucleic Acids Res.* 39: 3972-3987.
 - Arthanari, Y., A. Pluen, R. Rajendran, H. Aojula, and C. Demonacos. 2010. Delivery of therapeutic shRNA and siRNA by Tat fusion peptide targeting BCR-ABL fusion gene in Chronic Myeloid Leukemia cells. *J. Control Release* 145: 272-280.
 - Endoh, T., and T. Ohtsuki. 2009. Cellular siRNA delivery using cell-penetrating peptides modified for endosomal escape. *Adv. Drug Deliv. Rev.* 61: 704-709.
 - Eguchi, A., B. R. Meade, Y. C. Chang, C. T. Fredrickson, K. Willert, N. Puri, and S. F. Dowdy. 2009. Efficient siRNA delivery into primary cells by a peptide transduction domain-dsRNA binding domain fusion protein. *Nat. Biotechnol.* 27: 567-571.
 - Endoh, T., M. Sisido, and T. Ohtsuki. 2008. Cellular siRNA delivery mediated by a cell-permeant RNA-binding protein and photoinduced RNA interference. *Bioconjug. Chem.* 19: 1017-1024.
 - Lindgren, M., K. Rosenthal-Aizman, K. Saar, E. Eiriksdottir, Y. Jiang, M. Sassian, P. Ostlund, M. Hallbrink, and U. Langel. 2006. Overcoming methotrexate resistance in breast cancer tumour cells by the use of a new cell-penetrating peptide. *Biochem. Pharmacol.* 71: 416-425.
 - Dubikovskaya, E. A., S. H. Thorne, T. H. Pillow, C. H. Contag, and P. A. Wender. 2008. Overcoming multidrug resistance of small-molecule therapeutics through conjugation with releasable octaarginine transporters. *Proc. Natl. Acad. Sci. U. S. A.* 105: 12128-12133
 - Tacke, P. J., V. de, I. R. Torensma, and C. G. Figdor. 2007. Dendritic-cell immunotherapy: from *ex vivo* loading to *in vivo* targeting. *Nat. Rev. Immunol.* 7: 790-802.
 - Palucka, K., and J. Banchereau. 2012. Cancer immunotherapy via dendritic cells. *Nat. Rev. Cancer* 12: 265-277.
 - Yamashita, M., M. Kimura, M. Kubo, C. Shimizu, T. Tada, R. M. Perlmutter, and T. Nakayama. 1999. T cell antigen re-

- ceptor-mediated activation of the Ras/mitogen-activated protein kinase pathway controls interleukin 4 receptor function and type-2 helper T cell differentiation. *Proc. Natl. Acad. Sci. U. S. A.* 96: 1024-1029.
36. Myou, S., X. Zhu, S. Myo, E. Boetticher, A. Y. Meliton, J. Liu, N. M. Munoz, and A. R. Leff. 2003. Blockade of airway inflammation and hyperresponsiveness by HIV-TAT-dominant negative Ras. *J. Immunol.* 171: 4379-4384.
 37. Fruman, D. A., F. Mauvais-Jarvis, D. A. Pollard, C. M. Yballe, D. Brazil, R. T. Bronson, C. R. Kahn, and L. C. Cantley. 2000. Hypoglycaemia, liver necrosis and perinatal death in mice lacking all isoforms of phosphoinositide 3-kinase p85 alpha. *Nat. Genet.* 26: 379-382
 38. Myou, S., A. R. Leff, S. Myo, E. Boetticher, J. Tong, A. Y. Meliton, J. Liu, N. M. Munoz, and X. Zhu. 2003. Blockade of inflammation and airway hyperresponsiveness in immune-sensitized mice by dominant-negative phosphoinositide 3-kinase-TAT. *J. Exp. Med.* 198: 1573-1582.
 39. Brownlie, R. J. and R. Zamoyka. 2013. T cell receptor signaling networks: branched, diversified and bounded. *Nat. Rev. Immunol.* 13: 257-269.
 40. Kim, K. D., J. M. Choi, W. J. Chae, and S. K. Lee. 2009. Synergistic inhibition of T-cell activation by a cell-permeable ZAP-70 mutant and ctCTLA-4. *Biochem. Biophys. Res. Commun.* 381: 355-360.
 41. Kaplan, M. H., U. Schindler, S. T. Smiley, and M. J. Grusby. 1996. Stat6 is required for mediating responses to IL-4 and for development of Th2 cells. *Immunity* 4: 313-319.
 42. McCusker, C. T., Y. Wang, J. Shan, M. W. Kinyanjui, A. Villeneuve, H. Michael, and E. D. Fixman. 2007. Inhibition of experimental allergic airways disease by local application of a cell-penetrating dominant-negative STAT-6 peptide. *J. Immunol.* 179: 2556-2564.
 43. Ivanov, I. I., B. S. McKenzie, L. Zhou, C. E. Tadokoro, A. Lepelley, J. J. Lafaille, D. J. Cua, and D. R. Littman. 2006. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17⁺ T helper cells. *Cell* 126: 1121-1133.
 44. Park, T. Y., S. D. Park, J. Y. Cho, J. S. Moon, N. Y. Kim, K. Park, R. H. Seong, S. W. Lee, T. Morio, A. L. Bothwell, and S. K. Lee. 2014. RORgammat-specific transcriptional interatomic inhibition suppresses autoimmunity associated with TH17 cells. *Proc. Natl. Acad. Sci. U. S. A.* 111: 18673-18678.
 45. Walunas, T. L., D. J. Lenschow, C. Y. Bakker, P. S. Linsley, G. J. Freeman, J. M. Green, C. B. Thompson, and J. A. Bluestone. 1994. CTLA-4 can function as a negative regulator of T cell activation. *Immunity* 1: 405-413.
 46. Choi, J. M., M. H. Ahn, W. J. Chae, Y. G. Jung, J. C. Park, H. M. Song, Y. E. Kim, J. A. Shin, C. S. Park, J. W. Park, T. K. Park, J. H. Lee, B. F. Seo, K. D. Kim, E. S. Kim, D. H. Lee, S. K. Lee, and S. K. Lee. 2006. Intranasal delivery of the cytoplasmic domain of CTLA-4 using a novel protein transduction domain prevents allergic inflammation. *Nat. Med.* 12: 574-579.
 47. Choi, J. M., S. H. Kim, J. H. Shin, T. Gibson, B. S. Yoon, D. H. Lee, S. K. Lee, A. L. Bothwell, J. S. Lim, and S. K. Lee. 2008. Transduction of the cytoplasmic domain of CTLA-4 inhibits TcR-specific activation signals and prevents collagen-induced arthritis. *Proc. Natl. Acad. Sci. U. S. A.* 105: 19875-19880.
 48. Lim, S., W. J. Kim, Y. H. Kim, S. Lee, J. H. Koo, J. A. Lee, H. Yoon, D. H. Kim, H. J. Park, H. M. Kim, H. G. Lee, K. J. Yun, J. U. Lee, S. J. Hun, K. L. Kyun, J. Doh, H. Kim, S. K. Lee, A. L. Bothwell, M. Suh, and J. M. Choi. 2015. dNP2 is a blood-brain barrier-permeable peptide enabling ctCTLA-4 protein delivery to ameliorate experimental autoimmune encephalomyelitis. *Nat. Commun.* 6: 8244.
 49. Jo, D., D. Liu, S. Yao, R. D. Collins, and J. Hawiger. 2005. Intracellular protein therapy with SOCS3 inhibits inflammation and apoptosis. *Nat. Med.* 11: 892-898
 50. Choi, J. M., J. H. Shin, M. H. Sohn, M. J. Harding, J. H. Park, Z. Tobiasova, D. Y. Kim, S. E. Maher, W. J. Chae, S. H. Park, C. G. Lee, S. K. Lee, and A. L. Bothwell. 2010. Cell-permeable Foxp3 protein alleviates autoimmune disease associated with inflammatory bowel disease and allergic airway inflammation. *Proc. Natl. Acad. Sci. U. S. A.* 107: 18575-18580.
 51. Baeuerle, P. A., and T. Henkel. 1994. Function and activation of NF-kappa B in the immune system. *Annu. Rev. Immunol.* 12: 141-179.
 52. Israel, A. 2010. The IKK complex, a central regulator of NF-kappaB activation. *Cold Spring Harb. Perspect. Biol.* 2: a000158.
 53. Choi, M., S. Rolle, M. Wellner, M. C. Cardoso, C. Scheidereit, F. C. Luft, and R. Kettritz. 2003. Inhibition of NF-kappaB by a TAT-NEMO-binding domain peptide accelerates constitutive apoptosis and abrogates LPS-delayed neutrophil apoptosis. *Blood* 102: 2259-2267.
 54. Macian, F. 2005. NFAT proteins: key regulators of T-cell development and function. *Nat. Rev. Immunol.* 5: 472-484.
 55. Aramburu, J., M. B. Yaffe, C. Lopez-Rodriguez, L. C. Cantley, P. G. Hogan, and A. Rao. 1999. Affinity-driven peptide selection of an NFAT inhibitor more selective than cyclosporin A. *Science* 285: 2129-2133.
 56. Choi, J. M., J. H. Sohn, T. Y. Park, J. W. Park, and S. K. Lee. 2012. Cell permeable NFAT inhibitory peptide Sim-2-VIVIT inhibits T-cell activation and alleviates allergic airway inflammation and hyper-responsiveness. *Immunol. Lett.* 143: 170-176.
 57. Gaestel, M. 2006. MAPKAP kinases - MKs - two's company, three's a crowd. *Nat. Rev. Mol. Cell Biol.* 7: 120-130.
 58. Brugnano, J. L., B. K. Chan, B. L. Seal, and A. Panitch. 2011. Cell-penetrating peptides can confer biological function: regulation of inflammatory cytokines in human monocytes by MK2 inhibitor peptides. *J. Control Release* 155: 128-133.
 59. Moschos, S. A., S. W. Jones, M. M. Perry, A. E. Williams, J. S. Erjefalt, J. J. Turner, P. J. Barnes, B. S. Sproat, M. J. Gait, and M. A. Lindsay. 2007. Lung delivery studies using siRNA conjugated to TAT(48-60) and penetratin reveal peptide induced reduction in gene expression and induction of innate immunity. *Bioconjug. Chem.* 18: 1450-1459.
 60. Fisher, L., U. Soomets, T. Cortes, V. L. Chilton, Y. Jiang, U. Langel, and K. Iverfeldt. 2004. Cellular delivery of a double-stranded oligonucleotide NFkappaB decoy by hybridization to complementary PNA linked to a cell-penetrating peptide. *Gene Ther.* 11: 1264-1272.
 61. Lee, S. W., J. H. Kim, M. C. Park, Y. B. Park, W. J. Chae, T. Morio, D. H. Lee, S. H. Yang, S. K. Lee, S. K. Lee, and S. K. Lee. 2012. Alleviation of rheumatoid arthritis by cell-transducible methotrexate upon transcutaneous delivery. *Biomaterials*

- 33: 1563-1572.
62. Rothbard, J. B., S. Garlington, Q. Lin, T. Kirschberg, E. Kreider, P. L. McGrane, P. A. Wender, and P. A. Khavari. 2000. Conjugation of arginine oligomers to cyclosporin A facilitates topical delivery and inhibition of inflammation. *Nat. Med.* 6: 1253-1257.
 63. Banchereau, J., and R. M. Steinman. 1998. Dendritic cells and the control of immunity. *Nature* 392: 245-252.
 64. Steinman, R. M., and J. Banchereau. 2007. Taking dendritic cells into medicine. *Nature* 449: 419-426.
 65. Mukherji, B., N. G. Chakraborty, S. Yamasaki, T. Okino, H. Yamase, J. R. Sporn, S. K. Kurtzman, M. T. Ergin, J. Ozols, J. Meehan, and . 1995. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. *Proc. Natl. Acad. Sci. U. S. A.* 92: 8078-8082.
 66. Constantino, J., C. Gomes, A. Falcao, M. T. Cruz, and B. M. Neves. 2016. Antitumor dendritic cell-based vaccines: lessons from 20 years of clinical trials and future perspectives. *Transl. Res.* 168: 74-95.
 67. Florcken, A., J. Kopp, L. A. van, K. Movassaghi, A. Takvorian, K. Johrens, M. Mobs, C. Schonemann, B. Sawitzki, K. Egerer, B. Dorken, A. Pezzutto, and J. Westermann. 2013. Allogeneic partially HLA-matched dendritic cells pulsed with autologous tumor cell lysate as a vaccine in metastatic renal cell cancer: a clinical phase I/II study. *Hum. Vaccin. Immunother.* 9: 1217-1227.
 68. Hus, I., J. Rolinski, J. Tabarkiewicz, K. Wojas, A. Bojarska-Junak, J. Greiner, K. Giannopoulos, A. Dmoszynska, and M. Schmitt. 2005. Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early-stage B-cell chronic lymphocytic leukemia. *Leukemia* 19: 1621-1627.
 69. Pinzon-Charry, A., T. Maxwell, and J. A. Lopez. 2005. Dendritic cell dysfunction in cancer: a mechanism for immunosuppression. *Immunol. Cell Biol.* 83: 451-461.
 70. Orsini, E., A. Guarini, S. Chiaretti, F. R. Mauro, and R. Foa. 2003. The circulating dendritic cell compartment in patients with chronic lymphocytic leukemia is severely defective and unable to stimulate an effective T-cell response. *Cancer Res.* 63: 4497-4506.
 71. Schnurr, M., Q. Chen, A. Shin, W. Chen, T. Toy, C. Jenderek, S. Green, L. Miloradovic, D. Drane, I. D. Davis, J. Villadangos, K. Shortman, E. Maraskovsky, and J. Cebon. 2005. Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery. *Blood* 105: 2465-2472.
 72. de, V., I. W. J. Lesterhuis, N. M. Scharenborg, L. P. Engelen, D. J. Ruiter, M. J. Gerritsen, S. Croockewit, C. M. Britten, R. Torensma, G. J. Adema, C. G. Figdor, and C. J. Punt. 2003. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. *Clin. Cancer Res.* 9: 5091-5100.
 73. Jongmans, W., D. M. Tiemessen, V. van, I. P. F. Mulders, and E. Oosterwijk. 2005. Th1-polarizing capacity of clinical-grade dendritic cells is triggered by Ribomunyl but is compromised by PGE2: the importance of maturation cocktails. *J. Immunother.* 28: 480-487.
 74. Aarntzen, E. H., M. Srinivas, G. Schreiber, A. Heerschap, C. J. Punt, C. G. Figdor, W. J. Oyen, and V. de, I. 2013. Reducing cell number improves the homing of dendritic cells to lymph nodes upon intradermal vaccination. *Oncimmunology* 2: e24661.
 75. Lesterhuis, W. J., V. de, I., G. Schreiber, A. J. Lambeck, E. H. Aarntzen, J. F. Jacobs, N. M. Scharenborg, M. W. van de Rakt, A. J. de Boer, S. Croockewit, M. M. van Rossum, R. Mus, W. J. Oyen, O. C. Boerman, S. Lucas, G. J. Adema, C. J. Punt, and C. G. Figdor. 2011. Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients. *Clin. Cancer Res.* 17: 5725-5735.
 76. Guo, J., J. Zhu, X. Sheng, X. Wang, L. Qu, Y. Han, Y. Liu, H. Zhang, L. Huo, S. Zhang, B. Lin, and Z. Yang. 2007. Intratumoral injection of dendritic cells in combination with local hyperthermia induces systemic antitumor effect in patients with advanced melanoma. *Int. J. Cancer* 120: 2418-2425.
 77. Saji, H., W. Song, K. Furumoto, H. Kato, and E. G. Engleman. 2006. Systemic antitumor effect of intratumoral injection of dendritic cells in combination with local photodynamic therapy. *Clin. Cancer Res.* 12: 2568-2574.
 78. Fong, L., D. Brockstedt, C. Benike, L. Wu, and E. G. Engleman. 2001. Dendritic cells injected via different routes induce immunity in cancer patients. *J. Immunol.* 166: 4254-4259.
 79. Thurner, B., I. Haendle, C. Roder, D. Dieckmann, P. Keikavoussi, H. Jonuleit, A. Bender, C. Maczek, D. Schreiner, D. P. von den, E. B. Brocker, R. M. Steinman, A. Enk, E. Kampgen, and G. Schuler. 1999. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. *J. Exp. Med.* 190: 1669-1678.
 80. Mackensen, A., B. Herbst, J. L. Chen, G. Kohler, C. Noppen, W. Herr, G. C. Spagnoli, V. Cerundolo, and A. Lindemann. 2000. Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated *in vitro* from CD34(+) hematopoietic progenitor cells. *Int. J. Cancer* 86: 385-392.
 81. Aarntzen, E. H., M. Srinivas, J. H. De Wilt, J. F. Jacobs, W. J. Lesterhuis, A. D. Windhorst, E. G. Troost, J. J. Bonenkamp, M. M. van Rossum, W. A. Blokx, R. D. Mus, O. C. Boerman, C. J. Punt, C. G. Figdor, W. J. Oyen, and V. de, I. 2011. Early identification of antigen-specific immune responses *in vivo* by [18F]-labeled 3'-fluoro-3'-deoxy-thymidine ([18F]FLT) PET imaging. Dendritic cell dysfunction in cancer: a mechanism for immunosuppression. 108: 18396-18399.
 82. Palucka, A. K., H. Ueno, J. Connolly, F. Kerneis-Norvell, J. P. Blanck, D. A. Johnston, J. Fay, and J. Banchereau. 2006. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8⁺ T-cell immunity. *J. Immunother.* 29: 545-557.
 83. Murphy, G., B. Tjoa, H. Ragde, G. Kenny, and A. Boynton. 1996. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. *Prostate* 29: 371-380.
 84. Nair, S. K., M. Morse, D. Boczkowski, R. I. Cumming, L. Vasovic, E. Gilboa, and H. K. Lyerly. 2002. Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells. *Ann. Surg.* 235: 540-549.
 85. Okada, H., P. Kalinski, R. Ueda, A. Hoji, G. Kohanbash, T. E.

- Donegan, A. H. Mintz, J. A. Engh, D. L. Bartlett, C. K. Brown, H. Zeh, M. P. Holtzman, T. A. Reinhart, T. L. Whiteside, L. H. Butterfield, R. L. Hamilton, D. M. Potter, I. F. Pollack, A. M. Salazar, and F. S. Lieberman. 2011. Induction of CD8⁺ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. *J. Clin. Oncol.* 29: 330-336.
86. Reichardt, V. L., C. Y. Okada, A. Liso, C. J. Benike, K. E. Stockerl-Goldstein, E. G. Engleman, K. G. Blume, and R. Levy. 1999. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma—a feasibility study. *Blood* 93: 2411-2419.
87. Bonifaz, L., D. Bonnyay, K. Mahnke, M. Rivera, M. C. Nussenzweig, and R. M. Steinman. 2002. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8⁺ T cell tolerance. *J. Exp. Med.* 196: 1627-1638.
88. Klechevsky, E., A. L. Flamar, Y. Cao, J. P. Blanck, M. Liu, A. O'Bar, O. gouna-Deciati, P. Klucar, L. Thompson-Snipes, S. Zurawski, Y. Reiter, A. K. Palucka, G. Zurawski, and J. Banchereau. 2010. Cross-priming CD8⁺ T cells by targeting antigens to human dendritic cells through DCIR. *Blood* 116: 1685-1697.
89. Ni, L., I. Gayet, S. Zurawski, D. Duluc, A. L. Flamar, X. H. Li, A. O'Bar, S. Clayton, A. K. Palucka, G. Zurawski, J. Banchereau, and S. Oh. 2010. Concomitant activation and antigen uptake via human dectin-1 results in potent antigen-specific CD8⁺ T cell responses. *J. Immunol.* 185: 3504-3513.
90. Joffre, O. P., D. Sancho, S. Zelenay, A. M. Keller, and Reis e Sousa. 2010. Efficient and versatile manipulation of the peripheral CD4⁺ T-cell compartment by antigen targeting to DNGR-1/CLEC9A. *Eur. J. Immunol.* 40: 1255-1265.
91. Flacher, V., F. Sparber, C. H. Tripp, N. Romani, and P. Stoitzner. 2009. Targeting of epidermal Langerhans cells with antigenic proteins: attempts to harness their properties for immunotherapy. *Cancer Immunol. Immunother.* 58: 1137-1147.
92. Bozzacco, L., C. Trumpfheller, F. P. Siegal, S. Mehandru, M. Markowitz, M. Carrington, M. C. Nussenzweig, A. G. Piperno, and R. M. Steinman. 2007. DEC-205 receptor on dendritic cells mediates presentation of HIV gag protein to CD8⁺ T cells in a spectrum of human MHC I haplotypes. Dendritic cell dysfunction in cancer: a mechanism for immunosuppression. 104: 1289-1294.
93. Dubensky, T. W., Jr., and S. G. Reed. 2010. Adjuvants for cancer vaccines. *Semin. Immunol.* 22: 155-161.
94. Li, D., G. Romain, A. L. Flamar, D. Duluc, M. Dullaers, X. H. Li, S. Zurawski, N. Bosquet, A. K. Palucka, G. R. Le, A. O'Garra, G. Zurawski, J. Banchereau, and S. Oh. 2012. Targeting self- and foreign antigens to dendritic cells via DC-ASGPR generates IL-10-producing suppressive CD4⁺ T cells. *J. Exp. Med.* 209: 109-121.
95. Wang, R. F. and H. Y. Wang. 2002. Enhancement of antitumor immunity by prolonging antigen presentation on dendritic cells. *Nat. Biotechnol.* 20: 149-154.
96. Kronenberg, K., S. Brosch, F. Butsch, Y. Tada, N. Shibagaki, M. C. Udey, and S. E. von. 2010. Vaccination with TAT-antigen fusion protein induces protective, CD8(+) T cell-mediated immunity against *Leishmania major*. *J. Invest. Dermatol.* 130: 2602-2610.
97. Shibagaki, N., and M. C. Udey. 2002. Dendritic cells transduced with protein antigens induce cytotoxic lymphocytes and elicit antitumor immunity. *J. Immunol.* 168: 2393-2401.
98. Viehl, C. T., M. Becker-Hapak, J. S. Lewis, Y. Tanaka, U. K. Liyanage, D. C. Linehan, T. J. Eberlein, and P. S. Goedegebuure. 2005. A tat fusion protein-based tumor vaccine for breast cancer. *Ann. Surg. Oncol.* 12: 517-525.
99. Pouniotis, D. S., S. Esparon, V. Apostolopoulos, and G. A. Pietersz. 2011. Whole protein and defined CD8(+) and CD4(+) peptides linked to penetratin targets both MHC class I and II antigen presentation pathways. *Immunol. Cell Biol.* 89: 904-913.
100. Mitsui, H., T. Inozume, R. Kitamura, N. Shibagaki, and S. Shimada. 2006. Polyarginine-mediated protein delivery to dendritic cells presents antigen more efficiently onto MHC class I and class II and elicits superior antitumor immunity. *J. Invest. Dermatol.* 126: 1804-1812.
101. Derouazi, M., W. Di Berardino-Besson, E. Belnoue, S. Hoepner, R. Walther, M. Benkhoucha, P. Teta, Y. Dufour, M. C. Yacoub, A. M. Salazar, D. Martinvalet, P. Y. Dietrich, and P. R. Walker. 2015. Novel Cell-Penetrating Peptide-Based Vaccine Induces Robust CD4⁺ and CD8⁺ T Cell-Mediated Antitumor Immunity. *Cancer Res.* 75: 3020-3031.
102. Ziegler, A. 2008. Thermodynamic studies and binding mechanisms of cell-penetrating peptides with lipids and glycosaminoglycans. *Adv. Drug Deliv. Rev.* 60: 580-597.
103. Gump, J. M., R. K. June, and S. F. Dowdy. 2010. Revised role of glycosaminoglycans in TAT protein transduction domain-mediated cellular transduction. *J. Biol. Chem.* 285: 1500-1507.
104. Joffre, O. P., E. Segura, A. Savina, and S. Amigorena. 2012. Cross-presentation by dendritic cells. *Nat. Rev. Immunol.* 12: 557-569.
105. Cresswell, P., A. L. Ackerman, A. Giodini, D. R. Peaper, and P. A. Wearsch. 2005. Mechanisms of MHC class I-restricted antigen processing and cross-presentation. *Immunol. Rev.* 207: 145-157.
106. Shen, L., L. J. Sigal, M. Boes, and K. L. Rock. 2004. Important role of cathepsin S in generating peptides for TAP-independent MHC class I crosspresentation *in vivo*. *Immunity* 21: 155-165.
107. Brooks, N. A., D. S. Pouniotis, C. K. Tang, V. Apostolopoulos, and G. A. Pietersz. 2010. Cell-penetrating peptides: application in vaccine delivery. *Biochim. Biophys. Acta* 1805: 25-34.
108. Tacken, P. J., B. Joosten, A. Reddy, D. Wu, A. Eek, P. Laverman, A. Kretz-Rommel, G. J. Adema, R. Torensma, and C. G. Figdor. 2008. No advantage of cell-penetrating peptides over receptor-specific antibodies in targeting antigen to human dendritic cells for cross-presentation. *J. Immunol.* 180: 7687-7696.
109. Skotland, T., T. G. Iversen, M. L. Torgersen, and K. Sandvig. 2015. Cell-penetrating peptides: possibilities and challenges for drug delivery *in vitro* and *in vivo*. *Molecules* 20: 13313-13323.